Flashback Foreword: Single-Agent Anti–Programmed Cell Death Protein 1 Therapy for Refractory Solid Tumors
Authors: Robert G. Maki
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. January 27, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02437 Journal of Clinical Oncology - published online before print January 27, 2023 PMID: 36706734 Flashback Foreword: Single-Agent Anti–Programmed Cell Death Protein 1 Therapy for Refractory Solid Tumors Robert G. Maki , MD, PhD1,2xRobert G. MakiSearch for articles by this author Show More 1Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02437 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2010, Brahmer et al1 demonstrated the activity of a programmed cell death protein 1 inhibitor in patients with solid tumor for the first time, with the evidence of durable responses, dependence on programmed death-ligand 1 expression in some cancers for activity, a toxicity profile distinct from cytotoxic T-cell lymphocyte 4 inhibition, and ultimately US Food and Drug Administration approval in an expanding number of diagnoses. This study was a starting point to making immunotherapy a pillar of cancer therapy along with more traditional treatments.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Single-Agent Anti–Programmed Cell Death Protein 1 Therapy for Refractory Solid TumorsThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Robert G. MakiThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Bayer, Karyopharm Therapeutics, TRACON Pharma, Deciphera, Ipsen, Daiichi Sankyo/Lilly, PEEL Therapeutics, UpToDateSpeakers' Bureau: PERResearch Funding: Regeneron (Inst), Daiichi (Inst), Bayer (Inst), SpringWorks Therapeutics (Inst), Amgen (Inst), Astex Pharmaceuticals (Inst), Boehringer Ingelheim (Inst), Rain Therapeutics (Inst), BioAtla (Inst), C4 Therapeutics (Inst), Exelixis (Inst), InhibRx (Inst), PEEL Therapeutics (Inst), Presage Biosciences (Inst), SARC: Sarcoma Alliance for Research though Collaboration (Inst), SynOx (Inst), TRACON Pharma (Inst)Patents, Royalties, Other Intellectual Property: Uptodate: I write and edit chapters for their online text bookTravel, Accommodations, Expenses: TRACON Pharma, SpringWorks TherapeuticsOpen Payments Link: https://openpaymentsdata.cms.gov/physician/205679/summaryNo other potential conflicts of interest were reported. Companion Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates